N1-(S)-(4-(Phenylsulfonyl)piperazin-2-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine

ID: ALA3627858

Chembl Id: CHEMBL3627858

PubChem CID: 122192964

Max Phase: Preclinical

Molecular Formula: C24H35N5O2S

Molecular Weight: 457.64

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  NCCCCN(C[C@H]1CN(S(=O)(=O)c2ccccc2)CCN1)[C@H]1CCCc2cccnc21

Standard InChI:  InChI=1S/C24H35N5O2S/c25-13-4-5-16-28(23-12-6-8-20-9-7-14-27-24(20)23)18-21-19-29(17-15-26-21)32(30,31)22-10-2-1-3-11-22/h1-3,7,9-11,14,21,23,26H,4-6,8,12-13,15-19,25H2/t21-,23-/m0/s1

Standard InChI Key:  UAQQVOLUJKQMGC-GMAHTHKFSA-N

Alternative Forms

  1. Parent:

    ALA3627858

    ---

Associated Targets(Human)

CXCR4 Tclin C-X-C chemokine receptor type 4 (3338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 457.64Molecular Weight (Monoisotopic): 457.2511AlogP: 2.16#Rotatable Bonds: 9
Polar Surface Area: 91.56Molecular Species: BASEHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 10.21CX LogP: 2.08CX LogD: -1.28
Aromatic Rings: 2Heavy Atoms: 32QED Weighted: 0.56Np Likeness Score: -0.97

References

1. Zhao H, Prosser AR, Liotta DC, Wilson LJ..  (2015)  Discovery of novel N-aryl piperazine CXCR4 antagonists.,  25  (21): [PMID:25935642] [10.1016/j.bmcl.2015.04.036]

Source